Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Bromocriptine

Classification: A

Drug products: Parlodel, Pravidel, Pravidel®

ATC code: G02CB01, N04BC01

Substances: bromocriptine, bromocriptine mesylate

Summary

The main indication of bromocriptine is in combination with L-dopa in Parkinson’s disease. The substance is also used to abort lactation. Bromocriptine is also used for treatment of prolactinoma, tumor size has been shown to diminish similarly in men and women with macroadenomas.

The frequency of bromocriptine-resistant tumors seems to be higher in men.
 
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Bromocriptine is mainly indicated for treatment of Parkinsons’s disease in combination with levodopa. Furthermore, bromocriptine is indicated in patients with prolactin-secreting adenomas, reduction in tumor size has been seen in both men and women with macroadenama. Bromocriptine is also indicated in women needing to terminate lactation [1].

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of bromocriptine have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of bromocriptine have been found.

Adverse effects

Bromocriptine-resistant prolactinomas have been found to be more frequent in men than women. This sex difference is not directly explained by the predominance of large tumors in men, as the tumor size is not predictive of the response to bromocriptine therapy. This finding has been reported in several studies [2,3].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2013-03-26

References

  1. Bromocriptine. DailyMed [www]. US National Library of Medicine. [updated 2012-09-01, cited 2013-03-26]. länk
  2. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102-7. PubMed
  3. Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien). 2005;147:751-7; discussion 757-8. PubMed
  4. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Expertrådet för neurologiska sjukdomar

Approved by: Mia von Euler